MicroRNAs contribute to the pathogenesis of human cancer by regulating the expression of oncogenes and tumor suppressor genes. In fact, loss of miR-15a and miR-16-1 leads to overexpression of BCL2 and MCL1 and the development of CLL, while overexpression of miR-155 leads to the development of aggressive B cell malignancies, possibly through suppression of SHIP1 phosphatase. We have shown loss of miR-29s in lung cancer, AML and the aggressive form of CLL. We have also shown that miR-29s target directly the de novo DNA methyltransferases (DNMT3A and 3B) and indirectly the maintenance DNA methyltransferase 1 (DNMT1) and that loss of miR-29 family members results in overexpression of DNMT3A, 3B and 1. This leads to silencing of tumor suppressors through methylation of CpG islands of their promoters that can be reversed by transfection with miR-29s. Thus, loss of miR-29s and overexpression of DNMTs seem to cause epigenetic changes associated with tumor development. We are proposing three small clinical trials to validate that loss of miR-29 is a predictor of response to demethylating agents such as 5-azacytidine (5-Aza) and decitabine in lung cancer, AML and the aggressive form of CLL. We are also planning to validate the results of these trials in mouse models of the diseases. Thus, this program will result in major research and development innovations that will effectively be linked to long term improvement and growth in oncology, public health and health care delivery.

Public Health Relevance

We have observed striking responses to demethylating agents in tumors that have lost the expression of microRNAs (miR-29s) that target the DNA methyltransferases. We propose to carry out three small clinical trials to show that patients with lung cancer, AML and the aggressive form of CLL should be stratified on the basis of miR-29 expression, since the tumor cells that have lost mir-29s are killed by demethylating agents. We also intend to validate our hypothesis in mouse models.

National Institute of Health (NIH)
National Cancer Institute (NCI)
High Impact Research and Research Infrastructure Programs (RC2)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O9))
Program Officer
Timmer, William C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Valeri, Nicola; Braconi, Chiara; Gasparini, Pierluigi et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25:469-83
Galli, Roberta; Paone, Alessio; Fabbri, Muller et al. (2013) Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RAR? and tumor regression. Proc Natl Acad Sci U S A 110:9812-7
Fabbri, Muller; Paone, Alessio; Calore, Federica et al. (2012) MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 109:E2110-6
Kim, Taewan; Veronese, Angelo; Pichiorri, Flavia et al. (2011) p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208:875-83